Mudumala, Raj (2024) Industry perspective on a holistic container closure integrity approach to parenteral combination products. European journal of pharmaceutics and biopharmaceutics, 194. pp. 20-35. ISSN 09396411

Abstract

Biologics are being developed more and more as parenteral combination products with drug delivery devices. The maintenance of sterility is imperative for such medical devices throughout their life cycle. Therefore, the container closure integrity (CCI) should, preferably, be built into the overall process, and not just demonstrated during the final testing of the combination product. The integrity is an important Critical Quality Attribute (CQA) and in the scope of specific considerations and studies during the combination product life cycle i.e., design robustness, assembly processes, storage (to end of shelf life), and shipping prior to patient use. The goal of this paper is to summarize an industry holistic approach to ensure CCI, for a combination product, and to build a scientifically based justification that Quality (in terms of CCI) is built into the overall process. Current analytical approaches used for characterization or Good Manufacturing Practice (GMP) CCI testing during combination product development will be described. However, the use of quality by design (QbD) during product development can reduce or eliminate routine batch level or stability testing of the combination product.

Item Type:	Article
Keywords:	Container closure integrity Design control Holistic approach Industry perspective Quality by design
Date Deposited:	29 Aug 2024 00:46
Last Modified:	29 Aug 2024 00:46
URI:	https://oak.novartis.com/id/eprint/50848